The present invention provides a process for the preparation of 5-[[(2R,3S)-2-[(lR)-l-[3,5-bis(trifluoromethyl)phenyi]ethoxy]-3-(4-fluorophenyl)-4-morpholinyljmethyl]-1,2-dihydro-3H-1,2,4-triazol-3-one (Aprepitant) comprising condensation of 2-(R)-[(lR)-l-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(S)-(4-fluorophenyl...

A simple, cost-effective and time-saving container for oral pharmaceutical reconstitution products is provided which obviates the conventional cumbersome process of oral reconstitution dosage preparation. The container includes a dual chambered vessel having a bottom chamber for storing a first constituent and a top...

The present invention provides a process for the isolation of 4-amino-5-fluoro-l-[(2R,5S)-2-(hydroxymethyl)-l,3-oxathioIan-5-yl]-2(lH)-pyrimidinone (eintncitabine) of formula I from the reaction mixture obtained by reacting (lR,2S,5R)-menthyL(2S,5R)o-(4-amino-5-fluoro-2-oxo-l(2H)-pyrimidinyl)-K3-oxathiolane-2-carbox...

(EN)The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyc...

The present invention relates to the use of a compound of formula 1 a stereoisomer or a tautomer thereof or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof for the treatment of an inflammatory disorder. The invention further relates to a pharmaceutical composition comprising a com...

The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts pharmaceutically acceptable solvates pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention al...

The present invention provides a process for the preparation of 2-[(2-amino-l,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valine ester hydrochloride (valacyclovir hydrochloride) of formula I comprising deprotection of N-[(benzyloxy)carbonyl]-L-valine-2-[(2-amino-l,6-dihydro-6-oxo-9H-purin-9-yl) methoxy] ethyl este...

The present invention relates to chronotherapeutic pharmaceutical compositions and a method of preparing the same. The composition comprises of at least one active ingredient, a pH independent agent and a hydrophilic agent. The active ingredient in the composition is coated with the pH independent agent. The composi...

The present invention provides an improved process for preparation of N-[4-(3.4-dichlorophenyl)-3.4-dihydro-l-(2H)-naphthalenylidene]methanamine (ketimine) comprising condensation of 4-(3.4-dichlorophenyl)-3.4-dihydro-l-(2H)-naphlhalenone (sertralone) with monomethyl amine gas in the presence of a dehydrating agent ...

The present invention provides a process for the preparation of 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valine ester hydrochloride (valacyclovir hydrochloride) of formula I comprising deprotection of N-[(benzyloxy)carbonyl]-L-valine-2-[(2-amino-l,6-dihydro-6-oxo-9H-purin-9-yi) methoxyjethyl ester...

The present invention provides a connecting device for coupling a container containing volatile anesthetic agent to a vaporizer unit attached to an anesthetic administering machine. The connecting device comprising a receiving head adapted to be connected to the vaporizer and an adapter configured to be connected to...

The present invention provides a container for anesthetic agents with a cap defining an opening therein, said opening providing fluid communication between said interior space defined by said container and an external environment of said container and a cap/closure constructed to seal said opening defined in said co...

The present invention relates to an improved heater apparatus (50) for heating fluid using hot products, said heater apparatus (50) comprising; a chamber means (1); an inlet for fluid to be heated (2); an outlet for heated fluid (3); at least one heating means (20) for producing said hot products in said chamber...

A process for preparing (±)-cis- 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine (sertraline) and/ or a pharmaceutically acceptable acid addition salt thereof comprising hydrogenation of 4-(3,4-dichlorophenyl)-3-4-dihydro-N-methyl-1-naphthalenimine (sertraline-1-imine) in the presence of a polar...

The present invention encompasses a chronotherapeutic drug delivery system and a process for preparing the same. The drug delivery system comprises of a delayed immediate release active ingredient and a delayed extended release active ingredient. The delayed extended release active ingredient is released initially a...

This invention embodies a device and a method for transferring volatile fluid from a container to a receiver using the said device, the said device comprising an adapter configured to be secured to said container and a receiver sub assembly adapted to be secured to said receiver; said adapter and receiver sub assemb...

The present invention relates to pharmaceutical compositions. Particularly, the present invention relates to oral controlled release (CR) pharmaceutical compositions and processes for their preparation.

The present invention relates to a fast dissolving pharmaceutical composition containing lornoxicam or phannaceutically acceptable salts thereof as an active ingredient along with at least one alkalinizer, at least one organic acid and at least one phannaceutically acceptable excipient. The present invention also re...

The present invention provides a process for stereoselective preparation of N- [(1 S,2R)-2-hydroxy-3-nitro-l-(phenylmethyl)propyl]carbamic acid 1,1- dimethylethyl ester (Nitroalcohol) comprising asymmetric reduction of the carbonyl group in [(lS)-3-nitro-2-oxo-l-(phenylmethyl)propyl]carbamic acid 1,1-dimethylethyl...

The present invention provides a continuous process for the production of 1,2,2,2-tetrafluoroethyl difluoromethyl ether (desflurane) which comprises feeding continuously optimum molar quantities of l-chloro-2,2,2-trifluoroethyl difluoromethyl ether (CF3CHCIOCHF2, Isoflurane) and anhydrous hydrogen fluoride, in a rea...

The present invention provides a process for the preparation of key intermediate for the synthesis 5.6-dimethoxy-2-[[I-(phenylmethyl)-4-piperidinyI]methyl]-l-indanone hydrochloride (donepezil hydrochloride). The present invention particularly provides a process for the preparation of 5,6-dimethoxy-2-(4-pyridylmethyl...

The present invention provides a process for the preparation of racemic or chiral octahydro-6-(phenylmethyi)-lH-pyrrolo[3,4-b]pyridine of formula I, a key intermediate in the synthesis of moxifloxacin or its pharmaceutically acceptable salts. The process comprises reaction of racemic or chiral tetrahydro-6-(phenylme...

The present invention provides a continuous process for purification of crude Isoflurane to yield pure Isoflurane using an entrainer such as water miscible solvent. The solvents, water miscible solvent and water used in the purification process are recycled, making the process commercially viable and environment fri...

The present invention provides a process for the preparation of N-[(lS)-3-nitro-2-oxo-l-(phenylmethyl)propy]]carbamic acid, 1,1 -dimethylethy 1 ester (Nitroketone) of formula 1, comprising the steps of, (a) preparing a solution of N-(tert-butoxycarbonyl)-L-pheny]alanylimidazole in an organic solvent, (b) preparing a...

The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid an amino a hydroxyl and a sulfhydr...